MARIA ELENA GARCÍA MARTÍNEZ

García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MA, García García T, García-Garre E, Vicente V, Ayala de la Peña F. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5. PubMed PMID: 25432519; PubMed Central PMCID: PMC4303200.

AÑO: 2014; IF: 5.49

25432519

Luengo-Gil G, González-Billalabeitia E, Chaves-Benito A, García Martínez E, García Garre E, Vicente V, Ayala de la Peña F. Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Res Treat. 2015 Jun;151(3):577-87. doi: 10.1007/s10549-015-3421-4. PubMed PMID: 25967462.

AÑO: 2015; IF: 4.085

25967462

Luengo-Gil G, Gonzalez-Billalabeitia E, Perez-Henarejos SA, Navarro Manzano E, Chaves-Benito A, Garcia-Martinez E, Garcia-Garre E, Vicente V, Ayala de la Peña F. Angiogenic role of miR-20a in breast cancer. PLoS One. 2018 Apr 4;13(4):e0194638. doi: 10.1371/journal.pone.0194638. eCollection 2018. PubMed PMID: 29617404; PubMed Central PMCID: PMC5884522.

AÑO: 2018; IF: 2.776

29617404

Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.

AÑO: 2023; IF: 4.7

37313470

Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, Blaya Boluda N, Lloret Gil M, Aller A, de la Morena Barrio P, Garcia Garre E, Martinez Diaz F, Garcia Molina F, Chaves Benito A, Garcia-Martinez E, Ayala de la Pena F. Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes. Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286-x. Online ahead of print. PubMed PMID: 38453782.

AÑO: 2024; IF: 3.8

38453782